Endoscopic mucosal resection for early gastric cancer

Bennett, Cathy; Wang, Yiping; Pan, Tianyue

doi:10.1002/14651858.cd004276.pub3

Cited by 35 publications

(21 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[6][7][8][9][10] Moreover, different adjuvant and neoadjuvant chemotherapy (with or without with radiotherapy) regimens have been shown to provide significant survival advantage to patients with advanced gastric cancer. [11][12][13][14][15] These strategies require reliable staging procedures to ensure the most appropriate (ie, with the highest therapeutic index, the ratio between efficacy and toxicity) treatment for each patient, according to the principles of personalized medicine.…”

mentioning

confidence: 99%

EUS for the staging of gastric cancer: a meta-analysis

Mocellin

Marchet

Nitti

2011

Gastrointestinal Endoscopy

115

View full text Add to dashboard Cite

mentioning

confidence: 99%

EUS for the staging of gastric cancer: a meta-analysis

Mocellin

Marchet

Nitti

2011

Gastrointestinal Endoscopy

115

View full text Add to dashboard Cite

“…ESD was initially developed in Japan [1] for the treatment of early gastric cancer confined to the mucosa or submucosa without the presence of lymph node metastasis. Since its development, this type of treatment has been applied in different clinical situations and has been developed on a large scale in the East.…”

Section: Discussionmentioning

confidence: 99%

“…Endoscopic submucosal dissection (ESD) is a type of endoscopic mucosal resection (EMR). ESD has become the treatment of choice for early gastric cancer and flat precancerous lesions in the oesophagus and stomach since its invention in 1996 in Japan [1]. This type of procedure can be successfully used in the diagnosis and even treatment of submucosal lesions (radical treatment can be applied only for submucosal lesions arising from the lamina muscularis mucosae).…”

Section: Introductionmentioning

confidence: 99%

Significance of Interdisciplinary Cooperation in the Treatment of Upper Gastrointestinal Mucosal and Submucosal Lesions: A Single Centre Experience

et al. 2012

View full text Add to dashboard Cite

Background: Endoscopic submucosal dissection (ESD) was initially developed in Japan for the treatment of early gastric cancer. Meanwhile ESD has become the treatment of choice for mucosal and submucosal lesions of the oesophagus and stomach. Method: We retrospectively reviewed our data on ESD performed in the period from 2007 to 2011 for the treatment of 67 mucosal and 8 submucosal lesions. These procedures were applied for 60 patients (mean age 63.8 years; 37 female and 23 male). Results: In 4 patients, we found more than 1 lesion for which ESD was applied as a treatment procedure. In 3 patients, ESD was repeated for lesion recurrence in the same location. The ESD specimens were classified as having tumour-free margins in 64 (95.5%) cases; however, during follow-up we identified 7 (10.4%) patients with recurrent lesions, including 3 cases of recurrent hyperplastic polyps, 1 case of early gastric cancer located in the cardia region of the stomach, and 1 case of recurrent flat tubular adenoma in the antral part of the stomach. We experienced 6 cases (8.9%) of delayed post-procedural bleeding all of which were successfully controlled endoscopically. In 5 cases (7.5%), perforation complications occurred. Conclusion: Our first experience with ESD was not all smooth: while the complication rate did not exceed 10%, it was markedly higher than that stated in Eastern literature. We would like to put this down to the learning curve phenomenon. The close cooperation between gastroenterologists and abdominal surgeons was very important and will play a vital role for technological innovations and safety in abdominal medicine in the future.

show abstract

“…The value of EMR and ESD has been proven effective in the management of early gastric cancer in several retrospective and prospective cohort studies but lack of high quality randomized controlled trial remains a challenge before routine use of this approach worldwide (52)(53)(54)(55)(56)(57). Considering that bleeding risk does not differ between ESD and EMR and that the perforation risk does not usually lead to life-threatening disease, therefore the benefit of ESD can outweigh the overall harm when compared with EMR with the proviso that that the ESD is performed by experienced practitioners (58).…”

Section: Endoscopic Approaches For the Management For Gastric Cancer mentioning

confidence: 99%

Minimally invasive surgery for gastric cancer in UK: current status and future perspectives

Sajid¹,

Hebbar²,

Sayegh³

2017

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

The aim of this study is to review the literature and report the various minimally invasive methods used to treat gastric cancer in the UK and compare it with worldwide practice. Published randomised studies, non-randomised studies and case series reporting the use of minimal invasive approach to treat gastric cancer were retrieved from the search of standard medical electronic databases and their outcomes were highlighted suggesting their effectiveness. Several randomised, controlled trials and metaanalyses have proven the clinical and oncological safety of the laparoscopic gastrectomy for gastric cancer.Similarly, robot-assisted gastrectomy, EMR (endoscopic mucosal resection) and ESD (endoscopic submucosal dissection) have also been proven feasible and safe to treat gastric cancer of various stages in prospective and retrospective comparative studies. However, UK based studies on minimally invasive surgery to treat gastric cancer is scarce and the paucity of trials led to uncertain outcomes. Laparoscopic gastrectomy, robot-assisted gastrectomy, EMR and ESD are feasible procedures in terms of clinical and oncological safety but mainly being practiced in Asian countries with high prevalence of stomach cancer. The UK based practice is still small and limited but the introduction of MIGOCS and STOMACH trial might help to widen the application of this technique.

show abstract

Endoscopic mucosal resection for early gastric cancer

Abstract: There is a lack of randomised controlled trials in which endoscopic mucosal resection (EMR) is compared with gastrectomy for early gastric cancer. There is, therefore, a need for well-designed randomised controlled trials to determine the effects of EMR compared to gastrectomy.

Cited by 35 publications

References 43 publications

EUS for the staging of gastric cancer: a meta-analysis

EUS for the staging of gastric cancer: a meta-analysis

Significance of Interdisciplinary Cooperation in the Treatment of Upper Gastrointestinal Mucosal and Submucosal Lesions: A Single Centre Experience

Minimally invasive surgery for gastric cancer in UK: current status and future perspectives

Contact Info

Product

Resources

About